Geron Initiates Clinical Trial Of GRN163L In Combination With Paclitaxel And Bevacizumab In Patients With Breast Cancer
�Geron Corporation (Nasdaq: GERN) announced the enrollment of the number 1 patient in a clinical trial of its telomerase inhibitor do drugs, GRN163L, in locally recurrent or metastatic breast cancer.
